HER3-DXd showed promising clinical activity in patients with advanced NSCLC and active brain metastases, and could represent a novel treatment option in this setting.
[Articles] Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
The Lancet Oncology | | Thorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, Manuel Ruiz-Borrego, María Valero, Antonio Llombart-Cussac, María Gion, Richard Greil, Miriam Arumi, Marta Campolier, José Antonio Guerrero, Giulia Raimondi, Mario Mancino, Carlos Jiménez-Cortegana, Marta Vaz-Batista, Felicitas Oberndorfer, Maximilian Marhold, Anna Sophie Berghoff, Julia Furtner, Rupert Bartsch, Matthias Preusser
Topics: lung-cancer, blood-cancer, brain-cancer, clinical-trials, research